Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of Ophthalmology Times.
Determining the time to DME resolution with intravitreal aflibercept
October 9th 2021Speaking at the American Society of Retina Specialists 2021 annual meeting in San Antonio, Rishi P. Singh, MD, provided results of the VISTA and VIVID studies, and he pointed out that the findings could help physicians set expectations of DME therapy.
Read More
PANORAMA study outlines variables to watch when managing NPDR
October 9th 2021During a presentation at the American Society of Retina Specialists 2021 annual meeting in San Antonio, W. Lloyd Clark, MD, presented results of the PANORAMA Study. The focus of the study, Clark said, was to identify the factors that increase the risk of complications in patients with nonproliferative diabetic retinopathy to provide information for making decisions on treatment choices.
Read More
LIGHTSITE II: Photobiomodulation a novel therapy for dry AMD
September 12th 2021During a presentation at the EURETINA 2021 Virtual Congress, Prof. Ben Burton detailed how dry AMD patients treated with photobiomodulation therapy have seen improvements in best-corrected visual acuity 9 months after treatment.
Read More
Study: Better understanding is key to beating diabetes
September 12th 2021In a presentation at the EURETINA 2021 Virtual Conference, Tunde Peto, MD, PhD, pointed out that while complications associated with diabetes develop over a long period, ophthalmologists today have an excellent understanding of diabetes-related eye changes.
Read More
Brolucizumab injection offers improved vision in neovascular age-related macular degeneration
September 11th 2021In a presentation at the EURETINA 2021 Virtual Congress, Cristina Cristian, MD, noted that an injection of brolucizumab treatment in patients with neovascular age-related macular degeneration led to a median improvement in visual acuity (VA) of 10.5 letters and the drug was well-tolerated.
Read More
Gene-independent therapeutic strategies for retinal degeneration include optogenetic therapy
September 10th 2021During a presentation at the EURETINA 2021 Virtual Congress, José-Alain Sahel, MD, explains that optogenetics involves the use of artificial photoreceptors from specific retinal cells to restore vision by transferring a gene that encodes for a light-sensitive protein that causes neuronal cells to respond to light stimulation.
Read More
Real-World Ophthalmology: A new conference to help ophthalmologists starting practice
September 9th 2021This conference titled, “The Top Ten Things I Wish I Knew Sooner,” is the brainchild of Lisa M. Nijm, MD, JD, who has had the foresight to help young ophthalmologists negotiate the choppy waters of a new practice.
Read More
Facing the challenges of treating peripheral hemorrhagic polypoidal choroidal vasculopathy
September 9th 2021Treating the disease can be a challenge, and at the EURETINA 2021 Virtual Congress, Chekitaan Singh, MD, discussed a case study detailing the care of a patient who had already lost vision in one eye from a similar issue.
Read More